Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -321.11% | 105.17% | -74.46% | 20.50% | 31.46% |
| Total Depreciation and Amortization | 5.74% | 53.74% | 0.77% | 3.82% | -0.60% |
| Total Amortization of Deferred Charges | -54.89% | 48.31% | -21.14% | 57.19% | -61.07% |
| Total Other Non-Cash Items | 47.86% | -277.81% | 236.80% | 2.36% | -40.96% |
| Change in Net Operating Assets | -102.14% | -135.35% | -45.64% | -23.65% | 205.56% |
| Cash from Operations | 15.27% | -6.27% | -107.73% | 28.99% | 53.33% |
| Capital Expenditure | 85.75% | -348.02% | 33.55% | -226.88% | -19.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Investing | 85.75% | -76.41% | -68.75% | -226.88% | -19.23% |
| Total Debt Issued | -35.46% | 61.30% | 35.20% | -26.29% | -40.50% |
| Total Debt Repaid | -- | 100.00% | -160.33% | 69.69% | -58.90% |
| Issuance of Common Stock | 44.22% | -58.56% | -33.62% | 42.51% | 21.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -32.23% | 17.56% | -7.15% | 6.09% | -26.40% |
| Foreign Exchange rate Adjustments | 287.70% | -81.86% | 178.90% | -142.21% | -145.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.50% | -722.95% | -84.12% | 154.47% | 179.06% |